About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/26/2021.
This website is for US healthcare professionals

Log In to Bolder Science


Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/26/2021.

Characterization of Variable MARrcha's Diary Variables as a Useful Measure

Clinicaltrials.gov identifier NCT03942302

Recruitment Status Recruiting

First Posted May 8, 2019

Last update posted May 8, 2019

Study Description

Brief summary:

Validate a simple clinical tool to evaluate physical activity (the question "How many minutes does it walk per day?" Or equivalent), compared to the rest of the collected physical activity data (PROactive questionnaire and objective physical activity data by means of an accelerometer record) in patients with COPD.

  • Condition or Disease:Chronic Obstructive Pulmonary Disease
  • Intervention/Treatment:
  • Phase: N/A
Detailed Description

Observational, national and multicenter epidemiological study in adult patients with COPD that will take place in the consultations of specialists in pneumology under conditions of usual clinical practice and that will be developed in two visits per patient.

Study Design
  • Study Type: Observational [Patient Registry]
  • Estimated Enrollment: 10 participants
  • Observational Model: Other
  • Time Perspective: Other
  • Official Title: Characterization of Variable MARrcha's Diary Variables as a Useful Measure of Physical Activity in Patients With Physical COPD in Patients With COPD
  • Actual Study Start Date: March 2019
  • Estimated Primary Completion Date: December 2019
  • Estimated Study Completion Date: April 2020
Outcome Measures
  • Primary Outcome Measures: 1. Minutes of daily walking [ Time Frame: During the 7 days that the device has. ]
    For such effects, the level of physical activity will be determined through a unique question, formulated in 5 different ways, which aims to collect the minutes of physical activity or daily walking minutes. The one that best fits the objective of the study will be selected. The questions that will be asked will be: How many minutes do you walk per day, on average? How many minutes do you walk briskly a day, on average? How many minutes do you walk outside the home on average? How many minutes do you spend doing physical activity a day, on average? How many minutes per day do you engage in moderate to intense physical activity, such as brisk walking, cycling, working in the garden, swimming, dancing, etc., on average?
  • Secondary Outcome Measures: 1. Date of inclusion in the study [ Time Frame: day 9 ]
  • 2. Age [ Time Frame: day 9 ]
    [date of birth, day-month-year]
  • 3. Sex [ Time Frame: day 9 ]
    [male / female]
  • 4. Size [ Time Frame: day 9 ]
  • 5. Weight [ Time Frame: day 9 ]
  • 6. Body Mass Index [ Time Frame: day 9 ]
    (BMI) [kg / m2]
  • 7. Marital Status [ Time Frame: day 9 ]
    [single / married / separated / divorced / widowed]
  • 8. Family situation [ Time Frame: day 9 ]
    Coexistence situation [only (a) / accompanied) Has children? [if not] If yes, how many children? [and ages for each child] Does any child live in the family home? [if not] Number of children in the family home [ages of these children] Do you have grandchildren? [if not] If yes, how many grandchildren? [and ages for each grandchild] Care for your grandchildren on a regular basis? [if not] Age of each grandchild in care Frequency with which she takes care of grandchildren [times / week] Do you have dog / s? [if not. If yes, specify how many]
  • 9. Place of residence [ Time Frame: day 9 ]
    [house / flat / others, specify]
  • 10. Academic training [ Time Frame: day 9 ]
    [without studies, primary, secondary, university studies]
  • 11. Employment status [ Time Frame: day 9 ]
    [self-employed / self-employed / unemployed / retired (a) / household tasks / other, specify]
  • 12. Socioeconomic level [ Time Frame: day 9 ]
    family income 15000€/15000€-25000€/25000€-30000€/>30000€
  • 13. Smoking [ Time Frame: day 9 ]
    [yes / ex] If yes, how many cigarettes / day now? How many packages / year? How many years of current smoking? In the case of an ex-smoker, how many cigarettes / day did he smoke? How many packages / year did he smoke? How many years of previous smoking? How many years / months without smoking until the start of the study?
  • 14. Date [ Time Frame: day 9 ]
  • 15. Description of instruments and measures [ Time Frame: day 9 ]
    Spirometry is a test of lung function (flow and capacity) that evaluates the amount of air through exhalation. The forced spirometry, in particular, is based on making the patient after a maximum inspiration exhale all the air, in the shortest time possible. [forced expiratory volume the first second (FEV1) in milliliters / forced vital capacity (FVC) in milliliters / FEV1 / FVC ratio (FEV1%)
  • 16. FEV1 [ Time Frame: day 9 ]
    it is a measure of flow and is expressed in milliliters and is the maximum volume exhaled in the first second of a forced expiration. Its normal value is> 80% of the theoretical value.
  • 17. FVC [ Time Frame: day 9 ]
    it is a measurement of capacity that is expressed in milliliters and is the maximum volume of exhaled air with the maximum possible effort, based on the total volume that the patient expels from maximum inspiration to maximum expiration. Its normal value is> 80% of the theoretical value.
  • 18. FEV1% [ Time Frame: day 9 ]
    it is indicative of the percentage of the total volume expired during the first second. Its normal value is> 70-75% of the theoretical value.
  • 19. Phenotype of COPD [ Time Frame: day 9 ]
    [non-exacerbator / mixed COPD-asthma / exacerbation with emphysema /exacerbator with chronic bronchitis]
  • 20. Non-pharmacological treatment [ Time Frame: day 9 ]
    [smoking cessation / rehabilitation program / oxygen therapy / others, specify]
  • 21. Number and scope of treatment of exacerbations suffered in the last year [ Time Frame: day 9 ]
    [ambulatory / hospital]
  • 22. Date of the last moderate-severe exacerbation. [ Time Frame: day 9 ]
  • 23. Scales, questionnaires and indexes [ Time Frame: day 9 ]
    IMC FEV1% Dyspnea (from the modified MRC scale) Distance collected in the 6MW [meters] Serious exacerbations in the last 12 months (only visits to hospital emergencies or admissions are included) [number of exacerbations] Determination of the prognostic severity according to BODEX data [three levels: I (mild of 0-2 points), II (moderate, 3-4 points), III (severe, ≥5 points)]. COTE comorbidity index, calculated according to 10 comorbidities to be assessed with variable scores, between 1 and 6 points [see Annex 9 for the complete list of comorbidities to be analyzed]
  • 24. Spirometry [ Time Frame: day 9 ]
    FEV1: is a measure of flow and is expressed in milliliters and is the maximum volume expired in the first second of a forced expiration. Its normal value is> 80% of the theoretical value. FVC: is a measure of capacity that is expressed in milliliters and is the maximum volume of exhaled air with the maximum possible effort, based on the total volume that the patient expels from maximum inspiration to maximum expiration. Its normal value is> 80% of the theoretical value. Ratio FEV1 / FVC x 100 (FEV1%): it is indicative of the percentage of the total expired volume during the first second. Its normal value is> 70-75% of the theoretical value.
  • 25. BODE and BODEX Index (Annex 8) [ Time Frame: day 9 ]
    The BODE index integrates the BMI, the FEV1, the degree of dyspnea (through the data of the modified MRC scale) and the exercise capacity evaluated by means of a 6-minute walk test. The scores of each variable range from 0 to 3 (range 0-10). An increase in one point of the BODE index is associated with a 34% increase in mortality from all causes and 62% in mortality from respiratory causes. The BODEX index takes into account the number of severe exacerbations (visits to hospital emergencies and admissions) instead of the walking test. The scores for each variable range from 0 to 3 (range 0-9). If the BODEx index is ≥ 5 points, the exercise test will be taken into account to determine the level of severity. Three levels of prognostic severity of COPD will be established: I (mild of 0-2 points), II (moderate, 3-4 points), III (severe, ≥5 points).
  • 26. COTE comorbidity index (annex 9) [ Time Frame: day 9 ]
    The COTE index (Divo et al., 2012) describes 10 comorbidities: cancer (lung, esophagus, pancreas and breast) (6 points), other cancers (2 points), anxiety (in women, 6 points), liver cirrhosis (2 points), atrial fibrillation (2 points), diabetes with neuropathy (2 points), pulmonary fibrosis (2 points), congestive heart failure (1 point), gastroduodenal ulcer (1 point) and coronary disease (1 point) (range) 0-25). A score ≥ 4 increases more than 2 times the expected risk of death.
  • 27. Charlson comorbidity index (InCC) (Annex 10) [ Time Frame: day 9 ]
    The Charlson comorbidity index (Charlson et al., 1987) is a 10-year survival assessment system, depending on the age of the patient being evaluated and the comorbidities of the subject. In addition to age, it consists of 19 items, which if present, have been found to influence the patient's life expectancy. Each item has a weight in the index, which can be 1, 2, 3 and 6. The age ranges are also scored from 0 to 5.
  • 28. HADS questionnaire (Annex 11) [ Time Frame: day 9 ]
    It is a scale that evaluates patients' anxiety and depression status (Zigmond & Snaith, 1983). One of its main attractions is that it suppresses somatic symptoms so that it can be evaluated independently of the underlying somatic disease. It consists of 14 items on a Likert scale of 4 points (range 0 - 3) to assess anxiety and depression (7 items for each). The total score is the sum of the 14 items (range 0 - 42), and for each subscale the score is the sum of the 7 items (range 0 - 21). It is considered that between 0 and 7 it does not indicate case, between 8 and 10 it would be a doubtful case and the scores superior to 11 are, probably, cases in each one of the subscales.
  • 29. CAT Scale (Annex 12) [ Time Frame: day 9 ]
    The CAT scale (Jones et al., 2009) measures the impact that COPD is having on the well-being and daily life of patients. It consists of 8 items (cough, sputum, tightness in the chest, shortness of breath climbing slopes / stairs, limitation of activity in the home, confidence to leave home, sleep and energy). Each item is valued on a scale of 6 points with different formats semantically (from 0 to 5), with a total score from 0 to 40. A score between 0-10 would be indicative of a low impact of the disease.
  • 30. Modified MRC scale (Annex 13) [ Time Frame: day 9 ]
    The modified MRC scale (Mahler & Wells, 1988) uses a very simple grading system to obtain the degree of dyspnea of the patient. This scale does not define the sensation of drowning per se, but it shows the degree of alteration that said drowning exerts on a day-to-day basis. It consists of 5 degrees of physical activity that provokes dyspnea that ranges from 0 (no type of exercise is capable of inducing dyspnea) and 4 (dyspnea prevents the patient from leaving the house or doing activities such as dressing or grooming). A higher score would be indicative of a greater degree of functional limitation.
  • 31. PROactive questionnaire (Annex 14) [ Time Frame: day 9 ]
    This questionnaire about physical activity is a hybrid tool that combines results perceived by patients (PRO) and given physical activity objectives that come from the accelerometer (Gimeno-Santos et al., 2015). The version for clinical visit (Clinical visit PROactive PRO) will be used, which gathers the experiences of physical activity of the patients in the last 7 days. It consists of 12 questions and 2 variables of the accelerometer (14 items in total), with options on a Likert scale of 0 to 4 points, and with a score that ranges between 0 and 56 points.
  • 32. Accelerometer (Annex 15) [ Time Frame: from day 2 to 8 ]
    The accelerometer is a motion sensor that uses a pinzoelectric transducer to detect acceleration movements in any of the 3 space dimensions (antero-posterior, medial-lateral, and longitudinal). Continuous monitoring of the actual physical activity of each patient will be obtained through a triaxial accelerometer (Dynaport® MoveMonitor) for a week. The accelerometer will be placed on all participants on the day of the IC signature. The device will be programmed to start the measurement on the day following V0 (day 2). The patient will be instructed to carry the device 24 hours a day for the next 7 days (day 2-8).
  • 33. Proof of the march (PM6M) (Annex 16) [ Time Frame: day 9 ]
    It is a physical activity test to evaluate the effort capacity, being very simple and easy to perform, with the use of very little equipment (Holland et al., 2014, Singh et al., 2014). In this case, the maximum distance in meters that the patient travels in 6 minutes will be evaluated. Due to the learning factor demonstrated in this test, 2 tests will be carried out and the test in which the patient reached the greatest distance will be taken into account in the analysis.
  • 34. Questionnaire on motivation to perform physical activity. [ Time Frame: day 9 ]
    This is the translation into Spanish of the questionnaire developed by Danilack et al, 2014 It consists of 4 domains (motivation, confidence, physical environment and social support) For the general reasons of motivation and trust, the subjects were asked: In general, how motivated are you to walk every day? And How confident do you feel you can walk every day? with responses on a Likert scale from 1 to 10, where the highest scores reflect greater motivation and confidence. In addition, motivation and confidence were characterized to evaluate the reasons for walking and the confidence to exercise in different situations, including health reasons, bad weather, low energy, lack of time and fear of injury.
Eligibility Criteria
  • Ages Eligible for Study: 40 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
  • Sampling Method: Non-Probability Sample
  • Study Population: The population under study will be constituted by adult patients diagnosed with COPD. To avoid selection biases, each participating researcher will include in the study the first 10 patients who come to a pulmonology clinic with a clinical diagnosis of COPD and who meet the selection criteria.

Inclusion Criteria:

Adult patients, ≥ 40 years.

- Patients diagnosed with COPD according to the GOLD criteria: FEV1 / FVC
postbronchodilator <0.70 in a spirometry performed in the last 12 months. - Smokers or ex-smokers of ≥10 pack-years. - Patients with a minimum age in the diagnosis of COPD of at least 6 months. - Patients who accept their participation in the study and who have given their informed consent (IC) in writing to participate in it. Exclusion Criteria: - Patients whose clinical history data are not available. - Patients unable to understand the study questionnaires. - Patients with physical limitation (not caused by the respiratory disease, eg disability, orthopedic limitation, etc.) and / or psychic that prevents the proper conduct of the study. - Patients who present a moderate or severe exacerbation of COPD in the month prior to inclusion. - Patients with other chronic respiratory diseases other than COPD (such as cystic fibrosis, bronchiectasis of origin other than COPD, neoplasia, pneumonia). - Patients with serious cardiovascular or neurological diseases. - Hospital admission for any reason in the month prior to inclusion.

Contacts and Locations

Contact: Elisa Simón 910888877 elisa.simon@bioclever.com

Contact: Ester Salmerón 93 2172115 fucapneumo@gmail.com


Spain, Cataluña

Sponsors and Collaborators

Ferran Morell


Study Director: Ferran Morell Fundacio Catalana de Pneumologia

More Information
  • Responsible Party: Ferran Morell
  • ClinicalTrials.gov Identifier: NCT03942302 History of Changes
  • Other Study ID Numbers: FUC-EPO-2018-01
  • First Posted: May 8, 2019 Key Record Dates
  • Last Update Posted: May 8, 2019
  • Last Verified: May 2019
  • Individual Participant
    Data (IPD) Sharing
  • Plan to Share IPD: Undecided
  • Plan Description: Pending confirmation with sponsor
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive